IsoPlexis Reports Preliminary Full Year 2022 Revenue
January 12, 2023 16:05 ET
|
IsoPlexis Corporation
BRANFORD, Conn., Jan. 12, 2023 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today...
Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company
December 21, 2022 16:49 ET
|
IsoPlexis Corporation
Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate...
IsoPlexis Reports Third Quarter 2022 Financial Results
November 10, 2022 07:00 ET
|
IsoPlexis Corporation
BRANFORD, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today...
IsoPlexis to Participate in Upcoming Investor Conferences
November 09, 2022 07:00 ET
|
IsoPlexis Corporation
BRANFORD, Conn., Nov. 09, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today...
IsoPlexis to Report Third Quarter 2022 Financial Results on November 10, 2022
October 19, 2022 07:00 ET
|
IsoPlexis Corporation
BRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today...
IsoPlexis Announces First APAC Publication, Illustrating Early Impact of Codeplex Platform
September 13, 2022 07:00 ET
|
IsoPlexis Corporation
BRANFORD, Conn., Sept. 13, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO) (“IsoPlexis”), a company empowering labs to leverage the cells and proteome changing the course of human...
IsoPlexis Partners with MediMergent and The Center for Cancer and Blood Disorders in Study of AZD7442 for Prevention of COVID-19 Infection in Immuno-Compromised Cancer Patients
September 06, 2022 07:00 ET
|
IsoPlexis Corporation
BRANFORD, Conn., Sept. 06, 2022 (GLOBE NEWSWIRE) -- IsoPlexis (NASDAQ: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a...
IsoPlexis to Participate in the Morgan Stanley Global Healthcare Conference
August 31, 2022 07:00 ET
|
IsoPlexis Corporation
BRANFORD, Conn., Aug. 31, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO) (“IsoPlexis”), a company empowering labs to leverage the cells and proteome changing the course of human...
IsoPlexis Announces the Appointment of former Luminex Corporation Chairman and CEO, Nachum “Homi” Shamir to its Board of Directors
August 23, 2022 07:00 ET
|
IsoPlexis Corporation
BRANFORD, Conn., Aug. 23, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO) (“IsoPlexis”), a company empowering labs to leverage the cells and proteome changing the course of human...
IsoPlexis Reports Second Quarter 2022 Financial Results
August 10, 2022 07:00 ET
|
IsoPlexis Corporation
BRANFORD, Conn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today...